Guggenheim raised the firm’s price target on Vera Therapeutics (VERA) to $64 from $56 and keeps a Buy rating on the shares. After attending the American Society of Nephrology meeting this weekend, the firm says it “once again came away impressed” with the clinical profile for Vera’s atacicept in the treatment of immunoglobulin A nephropathy, or IgAN. Following the ASN meeting, the firm increased its atacicept probability of success view to 85% from 80% and its market penetration rates for the APRIL/BAFF class and for atacicept specifically, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
- Vera Therapeutics initiated with an Outperform at Scotiabank
- Vera Therapeutics Expands Atacicept Autoimmune Kidney Studies
- Vera Therapeutics to expand development pipeline for atacicept
- Vera Therapeutics to report results from ORIGIN Phase 2b clinical trial